Muto S, Okada T, Yasuda M, et al. Drug Healthc Patient Saf. 2017;9:93–104.On page 97, ‘Discussion’ section, lines 10–13, left column, the sentence: ‘Similarly, placebo patients who crossed over onto active treatment ...
Nakajima K +5 more
core
MEDA-PKD: a dynamic, real-time analytics platform for precision care in autosomal dominant polycystic kidney disease. [PDF]
Grundmann F +24 more
europepmc +1 more source
Effects of Psychological Counselling Combined With Tolvaptan on Depression, Anxiety, and Quality of Life in Patients With Traumatic Brain Injury and Hyponatremia. [PDF]
Wang Y, Wang Z, Xiong Z, Xu H.
europepmc +1 more source
Clinical Trial of Tolvaptan in Pediatric ADPKD: Two-Year, Open-Label Extension. [PDF]
Mekahli D +12 more
europepmc +1 more source
Association Between Tolvaptan Exposure and Venous Thromboembolism Risk in ADPKD: A Real-World Propensity-Matched EHR Study. [PDF]
Chen TP, Tsai SF.
europepmc +1 more source
Short-term effects of an SGLT2 inhibitor on divalent ions in autosomal dominant polycystic kidney disease: a randomized crossover trial. [PDF]
Roth L +8 more
europepmc +1 more source
Comment on Yamazaki et al. Long-Term Effects of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Predictors of Treatment Response and Safety over 6 Years of Continuous Therapy. <i>Int. J. Mol. Sci.</i> 2024, <i>25</i>, 2088. [PDF]
De Rosa LI +7 more
europepmc +1 more source
The Role of Genetic Testing in Tolvaptan Decision Making: A Case of Atypical Cystic Kidney Disease Associated With CYP24A1. [PDF]
Ellabbad MM +5 more
europepmc +1 more source
Satoru Muto,1 Tadashi Okada,2 Moriyoshi Yasuda,3 Hidetsugu Tsubouchi,4 Koji Nakajima,4 Shigeo Horie1,5 1Department of Advanced Informatics for Genetic Disease, Juntendo University Graduate School of Medicine, Tokyo, 2Department of Clinical Development ...
Nakajima K +5 more
core
Vaptans: A Narrative Review of Pharmacokinetics, Pharmacogenetics, and Clinical Applications. [PDF]
Lica-Miler M +6 more
europepmc +1 more source

